Advances in brain targeting and drug delivery of anti-HIV therapeutic agents

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Opinion on Drug Delivery

• Publication date

  2013-06-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/17425247.2013.781999PMID 23510097
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers.

  2012cited by this paper
• NeuroAIDS

  2012cited by this paper
• RES and brain targeting stavudine-loaded solid lipid nanoparticles for AIDS therapy

  2012cited by this paper
• Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy

  2011cited by this paper
• Bioavailability of Δ9-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits

  2011cited by this paper
• Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal zidovudine delivery to the brain.

  2011cited by this paper
• Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses

  2010cited by this paper
• Structure and function of the blood-brain barrier.

  2010cited by this paper
• Nanotechnology applications for improved delivery of antiretroviral drugs to the brain.

  2010cited by this paper
• Magnetic nanoformulation of azidothymidine 5’-triphosphate for targeted delivery across the blood–brain barrier

  2010cited by this paper
• Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1

  2010cited by this paper
• Drug Delivery to the Central Nervous System

  2010cited by this paper
• The role of the blood-CNS barrier in CNS disorders and their treatment.

  2010cited by this paper
• HIV-Associated Neurocognitive Disorder: Pathogenesis and Therapeutic Opportunities

  2010cited by this paper
• Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead.

  2009cited by this paper
• Preparation of a 3'-azido-3'-deoxythymidine (AZT) derivative, which is blood-brain barrier permeable.

  2009cited by this paper
• Drug interactions at the blood-brain barrier: fact or fantasy?

  2009cited by this paper
• Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases

  2009cited by this paper
• The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further research

  2009cited by this paper
• Targeting anti-HIV drugs to the CNS

  2009cited by this paper
• NanoART, neuroAIDS and CNS drug delivery.

  2009cited by this paper
• Corrigendum to “The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further research” [Antiviral Res. 82 (2) (2009) A99–A109]

  2009cited by this paper
• AZT 5′-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells

  2009cited by this paper
• Solid Lipid Nanoparticles Enhance the Delivery of the HIV Protease Inhibitor, Atazanavir, by a Human Brain Endothelial Cell Line

  2008cited by this paper
• Targeted brain delivery of 17β-estradiol via nasally administered water soluble prodrugs

  2008cited by this paper
• Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors.

  2008cited by this paper
• N-acetylcysteine prevents HIV gp 120-related damage of human cultured astrocytes: correlation with glutamine synthase dysfunction

  2007cited by this paper
• Novel Delivery System Enhances Efficacy of Antiretroviral Therapy in Animal Model for HIV-1 Encephalitis

  2007cited by this paper
• Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages.

  2007cited by this paper
• Evaluation of effect of ephedrine on the transport of drugs from the nasal cavity to the systemic circulation and the central nervous system

  2007cited by this paper
• Optimization of Lipid-Indinavir Complexes for Localization in Lymphoid Tissues of HIV-Infected Macaques

  2006cited by this paper
• Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites

  2006cited by this paper
• Structure-activity relationships in platelet-activating factor. Part 14: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 activity.

  2006cited by this paper
• Human immunodeficiency virus and the central nervous system.

  2006cited by this paper
• Design, synthesis, and membrane-translocation studies of inositol-based transporters.

  2006cited by this paper
• Retroviral DNA integration and the DNA damage response

  2005cited by this paper
• Molecular and cellular mechanisms of neuronal cell death in HIV dementia

  2005cited by this paper
• Ester Derivatives of Nucleoside Inhibitors of Reverse Transcriptase: 1. Molecular Transport Systems for 3′-Azido-3′-Deoxythymidine and 2′,3′-Didehydro-3′-Deoxythymidine

  2005cited by this paper
• Microdialysis evaluation of the brain distribution of stavudine following intranasal and intravenous administration to rats.

  2005cited by this paper
• Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus.

  2005cited by this paper
• ACNU, MTX And 5-FU Penetration of Rat Brain Tissue and Tumors

  2004cited by this paper
• Targeted therapy for brain tumours

  2004cited by this paper
• Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity.

  2004cited by this paper
• Is nose‐to‐brain transport of drugs in man a reality?

  2004cited by this paper
• HIV‐1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells

  2003influential reference
• HIV Mucosal Vaccine: Nasal Immunization with gp160-Encapsulated Hemagglutinating Virus of Japan-Liposome Induces Antigen-Specific CTLs and Neutralizing Antibody Responses1

  2003cited by this paper
• Human immunodeficiency virus type 1 Tat protein directly activates neuronal N-methyl-d-aspartate receptors at an allosteric zinc-sensitive site

  2003cited by this paper
• The roles of cellular factors in retroviral integration.

  2003cited by this paper
• Investigation of the mechanism of enhancement of central nervous system delivery of 2'-beta-fluoro-2',3'-dideoxyinosine via a blood-brain barrier adenosine deaminase-activated prodrug.

  2002cited by this paper
• The Impact of Efflux Transporters in the Brain on the Development of Drugs for CNS Disorders

  2002cited by this paper
• A meta-analysis of the neuropsychological sequelae of HIV infection

  2002cited by this paper
• Transepithelial Transport of Prodrugs of the HIV Protease Inhibitors Saquinavir, Indinavir, and Nelfinavir Across Caco-2 Cell Monolayers

  2002cited by this paper
• Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir.

  2001cited by this paper
• Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments.

  2001cited by this paper
• Nanoparticulate systems for brain delivery of drugs.

  2001cited by this paper
• Biodegradable polymer implants to treat brain tumors.

  2001cited by this paper
• Transporter-mediated permeation of drugs across the blood-brain barrier.

  2000cited by this paper
• PMS-601, a New Platelet-Activating Factor Receptor Antagonist That Inhibits Human Immunodeficiency Virus Replication and Potentiates Zidovudine Activity in Macrophages

  2000cited by this paper
• Synthesis and Anti-HIV Activity of Prodrugs Derived from Saquinavir and Indinavir

  2000cited by this paper
• Human Immunodeficiency Virus-Associated Dementia

  1999cited by this paper
• HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.

  1999cited by this paper
• Role of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor

  1999cited by this paper
• Platelet-activating Factor Receptor Activation

  1998cited by this paper
• Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain.

  1998cited by this paper
• Targeted therapy for brain tumours

  1998cited by this paper
• Low blood-brain barrier permeability to azidothymidine (AZT), 3TC, and thymidine in the rat.

  1998influential reference
• Effects of physicochemical properties and other factors on systemic nasal drug delivery.

  1998cited by this paper
• Intranasal drug delivery.

  1998cited by this paper
• Structure-internalization relationship for adsorptive-mediated endocytosis of basic peptides at the blood-brain barrier.

  1997cited by this paper
• Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption.

  1997cited by this paper
• In vivo evidence for carrier-mediated efflux transport of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system.

  1997cited by this paper
• In Vivo Evidence for Carrier-Mediated Efflux Transport of 3 (cid:57) -Azido-3 (cid:57) -Deoxythymidine and 2 (cid:57) ,3 (cid:57) -Dideoxyinosine Across the Blood-Brain Barrier via a Probenecid-Sensitive Transport System 1

  1997cited by this paper
• Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels.

  1997cited by this paper
• The passage of azidodeoxythymidine into and within the central nervous system: does it follow the parent compound, thymidine?

  1997cited by this paper
• Localization of Purine Metabolizing Enzymes in Bovine Brain Microvessel Endothelial Cells: An Enzymatic Blood-Brain Barrier for Dideoxynucleosides?

  1996cited by this paper
• The Blood‐brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System

  1996cited by this paper
• In vivo biodistribution, pharmacokinetic parameters, and brain uptake of 5-halo-y-methoxy(or ethoxy)-5,6-dihydro-3'-azido-3'-deoxythymidine diastereomers as potential prodrugs of 3'-azido-3'-deoxythymidine.

  1996cited by this paper
• Identification of a saturable uptake system for deoxyribonucleosides at the blood-brain and blood-cerebrospinal fluid barriers.

  1996cited by this paper
• Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro

  1996cited by this paper
• Dementia Associated with the Acquired Immunodeficiency Syndrome

  1995cited by this paper
• Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome.

  1995cited by this paper
• Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin

  1994cited by this paper
• AIDS‐Related Dementia and Calcium Homeostasis a

  1994cited by this paper
• Synthesis, in vitro biological stability, and anti-HIV activity of 5-halo-6-alkoxy(or azido)-5,6-dihydro-3'-azido-3'-deoxythymidine diastereomers as potential prodrugs to 3'-azido-3'-deoxythymidine (AZT).

  1994cited by this paper
• Nasal absorption of zidovudine and its transport to cerebrospinal fluid in rats.

  1994cited by this paper
• In Vitro and in Vivo Transport of Zidovudine (AZT) Across the Blood–Brain Barrier and the Effect of Transport Inhibitors

  1994cited by this paper
• Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT.

  1993cited by this paper
• Biochemistry of multidrug resistance mediated by the multidrug transporter.

  1993cited by this paper
• Pathogenesis of human immunodeficiency virus infection

  1993cited by this paper
• Microdialysis study of zidovudine (AZT) transport in rat brain.

  1993cited by this paper
• Improved brain delivery of AZT using a glycosyl phosphotriester prodrug.

  1992cited by this paper
• Platelet-activating factor (PAF) receptor in rat brain: PAF mobilizes intracellular Ca2+ in hippocampal neurons.

  1992cited by this paper
• Human immunodeficiency virus and the central nervous system.

  1992cited by this paper
• Probenecid enhances central nervous system uptake of 2',3'-dideoxyinosine by inhibiting cerebrospinal fluid efflux.

  1991cited by this paper
• Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity.

  1991cited by this paper
• HIV‐Related Neurotoxicity

  1991cited by this paper
• Synthesis and biological evaluation of prodrugs of zidovudine.

  1990cited by this paper
• Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV.

  1990cited by this paper
• Probenecid Inhibits the Metabolic and Renal Clearances of Zidovudine (AZT) in Human Volunteers

  1990cited by this paper
• Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine.

  1990cited by this paper

• CEST MRI assessment of HIV-1-associated neurometabolic impairments in a humanized mouse model

  2025cites this paper
• CEST MRI Affirms HIV-1-Associated Neurometabolic Impairments in a Humanized Mouse Model

  2025cites this paper
• Multi-organ Targeting of HIV-1 Viral Reservoirs with Etravirine Loaded Nanostructured Lipid Carrier: An In-vivo Proof of Concept.

  2021cites this paper
• Intranasal drug delivery to overcome the blood–brain barrier

  2021cites this paper
• Approaches for CNS delivery of drugs – nose to brain targeting of antiretroviral agents as a potential attempt for complete elimination of major reservoir site of HIV to aid AIDS treatment

  2019cites this paper
• Indinavir-Loaded Nanostructured Lipid Carriers to Brain Drug Delivery: Optimization, Characterization and Neuropharmacokinetic Evaluation.

  2019cites this paper
• Nanoformulations: A Valuable Tool in the Therapy of Viral Diseases Attacking Humans and Animals

  2019cites this paper
• Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?

  2018cites this paper
• In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line

  2017cites this paper
• Small endogenous molecules as moiety to improve targeting of CNS drugs

  2017cites this paper
• In situ hybrid nano drug delivery system (IHN-DDS) of antiretroviral drug for simultaneous targeting to multiple viral reservoirs: An in vivo proof of concept.

  2017cites this paper
• Nanoneurotherapeutics approach intended for direct nose to brain delivery

  2015cites this paper
• Blood-brain barrier and neuro-AIDS.

  2015cites this paper
• Advances in Neurotherapeutic Delivery Technologies

  2015cites this paper
• Advances in Neurotherapeutic Delivery Technologies Chapter : Recent Developments in the Microemulsion Based Targeted Delivery of Neurotherapeutics

  2015cites this paper
• Neurologic complications of pediatric human immunodeficiency virus: implications for clinical practice and management challenges in the African setting.

  2014cites this paper
• Pericytes: brain-immune interface modulators

  2014cites this paper
• Targeted delivery of drugs to the brain.

  2013cites this paper